Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Standardization Protocol to Mitigate Progression of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Elderly Patients Treated with CD28 Co-Stimulatory Anti-CD19 CAR-T Cells - a Pilot Study

Gil Fridberg, Odelia Amit, Mohamad Ganayem, Felix Bukstein, Chava Perry, Irit Avivi Mazza, Ronit Gold, Ron Ram

Blood (2024) 144 (Supplement 1): 2086.

https://doi.org/10.1182/blood-2024-204837

Published: 2024

Journal Articles

Detection of B Cell Lymphomas By a Simple Epigenetic Blood Test

Blood (2024) 144 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2024-207707

Published: 2024

Journal Articles

Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching

Gil Fridberg, Odelia Amit, Liat Shargian, Ofrat Beyar Katz, Sigal Grisariu, Chava Perry, Ronit Gurion, Batia Avni, Tsila Zuckerman, Irit Avivi Mazza, Ron Ram

Blood (2023) 142 (Supplement 1): 4886.

https://doi.org/10.1182/blood-2023-188473

Published: 2023

Journal Articles

Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study

Ronit Gurion, Dmitri Guz, Meirav Kedmi, Chava Perry, Irit Avivi Mazza, Netanel A. Horowitz, Uri Abadi, Anat Gafter-Gvili, Pia Raanani, Neta Goldschmidt, Boaz Nachmias, Shlomzion Aumann

Blood (2023) 142 (Supplement 1): 5170.

https://doi.org/10.1182/blood-2023-186033

Published: 2023

Journal Articles

Clinical Significance of a Slightly Abnormal FLC Levels/Ratio

Dor Shpitzer, Yael C. Cohen, Chava Perry, Anat Reiner-Benaim, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 4777.

https://doi.org/10.1182/blood-2023-188508

Published: 2023

Journal Articles

Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Blood (2022) 140 (Supplement 1): 3816–3817.

https://doi.org/10.1182/blood-2022-165149

Published: 2022

Journal Articles

A Comprehensive Toxicity and Efficacy Analysis of Different Bridging Therapies Prior to Anti CD19-CAR-T Cell Therapy in Patients with DLBCL- a National Multi-Center Cohort Study

Ron Ram, Sigal Grisariu, Liat Shargian-Alon, Dana Yehudai-Ofir, Irit Avivi, Orit Gutfeld, Polina Stepensky, Tsila Zuckerman, Moshe Yeshurun, Odelia Amit, Batia Avni, Ronit Gurion, Yael Bar-On, Ofrat Beyar-Katz, Ronit Gold, Shimrit Ringelstein, Itai Levi, Tzvi Porges, Chava Perry

Blood (2021) 138 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2021-151085

Published: 2021

Journal Articles

COVID-19 in patients with CLL: how can we change the odds?

Yair Herishanu, Chava Perry

Blood (2021) 138 (18): 1652–1653.

https://doi.org/10.1182/blood.2021013286

Published: 2021

Journal Articles

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu, Irit Avivi, Anat Aharon, Gabi Shefer, Shai Levi, Yotam Bronstein, Miguel Morales, Tomer Ziv, Yamit Shorer Arbel, Lydia Scarfò, Erel Joffe, Chava Perry, Paolo Ghia

Blood (2021) 137 (23): 3165–3173.

https://doi.org/10.1182/blood.2021011568

Published: 2021

Includes: Supplemental data

Journal Articles

Anti-CD20-Mediated B Cell Depletion Is Associated with Reduced Osteoclastogenic Signals and Bone Mass Preservation: Clinical Observation in Patients with Follicular Lymphoma Supplemented By Animal Studies in a Murine Model

Albert Kolomansky, MD, Irit Kay, MD, Nathalie Ben-Califa, PhD, Anton Gorodov, BSc, Zamzam Awida, BSc, Ofer Sadovnic, MD, Maria Ibrahim, BSc, Tamar Liron, PhD, Sahar Hiram-Bab, PhD, Howard S. Oster, MD PhD, Nadav Sarid, MD, Chava Perry, MD PhD, Yankel Gabet, DMD, PhD, Moshe Mittelman, MD, Drorit Neumann, PhD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-142295

Published: 2020

Journal Articles

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Michal Ariela Raz, MD, Jon E. Arnason, MD, Osnat Bairey, MD PhD, Lev Shvidel, MD, Ariel Aviv, MD, Sharon Ben Baruch, MD, Chava Perry, MD PhD, Nadav Sarid, MD, David Varon, MD, Ilya Kirgner, MD, Yair Herishanu, MD, Irit Avivi

Blood (2019) 134 (Supplement_1): 4314.

https://doi.org/10.1182/blood-2019-125356

Published: 2019

Journal Articles

Is the Achievement of Pre-Autologous Transplant CR Necessary Indeed in Refractory/ Relapsed DLBCL Patients? a Retrospective Multicenter Study

Liat Shargian-Alon, MD, Hanna Bernstine, Galit Perets, MD, Ronit Gurion, Anat Gafter-Gvili, MD, Oren Pasvolsky, MD, Michal Navon Sela, Chava Perry, MD PhD, Irit Avivi, MD, Odelia Amit, MD, Pia Raanani, MD, Ron Ram, MD, Moshe Yeshurun, MD

Blood (2019) 134 (Supplement_1): 5703.

https://doi.org/10.1182/blood-2019-131229

Published: 2019

Journal Articles

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Yafit Segman, MD, Elena Ribakovsky, MD, Abraham Avigdor, MD, Vladimir Vainstein, MD, Neta Goldschmidt, MD, Shimrit Ringelstein Harlev, MD, Odit Gutwein, Uri Abadi, MD, Anatoly Nemets, MD, Orit Sofer, Najib Dally, MD, Kalman Filanovsky, MD, Merav Leiba, MD, Nadav Sarid, MD, Noam Benyamini, MD, Yair Herishanu, MD, Ron Ram, MD, Chava Perry, MD PhD, Irit Avivi

Blood (2019) 134 (Supplement_1): 5321.

https://doi.org/10.1182/blood-2019-124164

Published: 2019

Journal Articles

Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study

Sharon Ben Barouch, MD, Yair Herishanu, MD, Nadav Sarid, MD, Chava Perry, Irit Avivi, MD, Lev Shvidel, MD, Osnat Bairey, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Abraham Avigdor, MD, Neta Goldschmidt, MD, Eyal Lebel, MD, Orit Sofer

Blood (2017) 130 (Supplement 1): 1563.

https://doi.org/10.1182/blood.V130.Suppl_1.1563.1563

Published: 2017

Journal Articles

Wnt Signaling in Red Blood Cells

Rina Rosin-Arbesfeld, Michal Caspi, Ronen Siman-Tov, Yakir Levi, Chava Perry, MD PhD

Blood (2016) 128 (22): 4806.

https://doi.org/10.1182/blood.V128.22.4806.4806

Published: 2016

Journal Articles

Lymphocyte Activation Gene 3-a Novel Therapeutic Target in Chronic Lymphocytic Leukemia

Mika Shapiro, PhD, Ben-Zion Katz, PhD, Chava Perry, MD PhD, Clare Sun, MD, Nili Dezorella, M.Sc, Sigi Kay, PhD, Irit Avivi, MD, Adrian Wiestner, MD PhD, Herishanu Yair, MD

Blood (2016) 128 (22): 2018.

https://doi.org/10.1182/blood.V128.22.2018.2018

Published: 2016

Journal Articles

Real-Life Experience of Nivolumab in Heavily Pretreated Relapsed and Refractory Classical Hodgkin Lymphoma

Ohad Benjamini, MD, David Lavie, MD, Eldad J Dann, MD, Chava Perry, MDPhD, Ory Rouvio, MD, Olga Shvetz, MD, Anatoly Nemets, MD, Ruth Perets, MD PhD, Revital Saban, MD, Avichai Shimoni, MD, Dina Ben-Yehuda, MD, Arnon Nagler, Abraham Avigdor, MD

Blood (2016) 128 (22): 3008.

https://doi.org/10.1182/blood.V128.22.3008.3008

Published: 2016

Journal Articles

SLP76 Is Ectopically Expressed in Chronic Lymphocytic Leukemia Cells and Involves in B-Cell Receptor Signaling

Yair Herishanu, MD, Nili Dorozella, Mika Shapiro, PhD, Chava Perry, MDPhD, Ben-Zion Katz, PhD

Blood (2015) 126 (23): 1719.

https://doi.org/10.1182/blood.V126.23.1719.1719

Published: 2015

Journal Articles

Comparison of the Low Toxicity Tecam Conditioning Regimen to BEAM in Patients with Lymphoma Requiring Autologous Stem Cell Transplantation

Dana Rosenberg, MD, Erel Joffe, MDMSc, Uri Rozovski, MD, Chava Perry, MDPhD, Ilya Kirgner, MD, Svetlana Trestman, MD, Odelia Gur, Freddy Aviv, MD, Nadav Sarid, MD, Albert Kolomansky, MD, Lily Gepstein, Yair Herishanu, MD, Elizabeth Naparstek, MD

Blood (2015) 126 (23): 3188.

https://doi.org/10.1182/blood.V126.23.3188.3188

Published: 2015

Journal Articles

Primary Splenic Diffuse Large B-Cell Lymphoma (PS-DLBCL): Splenectomy Improves Survival

Osnat Bairey, MD, Lev Shvidel, MD, Chava Perry, MD PhD, Eldad J Dann, MD, Rosa Ruchlemer, MD, Tamar Tadmor, MD, Neta Goldschmidt, MD

Blood (2014) 124 (21): 4439.

https://doi.org/10.1182/blood.V124.21.4439.4439

Published: 2014

NARROW

Standardization Protocol to Mitigate Progression of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Elderly Patients Treated with CD28 Co-Stimulatory Anti-CD19 CAR-T Cells - a Pilot Study

Detection of B Cell Lymphomas By a Simple Epigenetic Blood Test

Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching

Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study

Clinical Significance of a Slightly Abnormal FLC Levels/Ratio

Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

A Comprehensive Toxicity and Efficacy Analysis of Different Bridging Therapies Prior to Anti CD19-CAR-T Cell Therapy in Patients with DLBCL- a National Multi-Center Cohort Study

COVID-19 in patients with CLL: how can we change the odds?

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Anti-CD20-Mediated B Cell Depletion Is Associated with Reduced Osteoclastogenic Signals and Bone Mass Preservation: Clinical Observation in Patients with Follicular Lymphoma Supplemented By Animal Studies in a Murine Model

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Is the Achievement of Pre-Autologous Transplant CR Necessary Indeed in Refractory/ Relapsed DLBCL Patients? a Retrospective Multicenter Study

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study

Wnt Signaling in Red Blood Cells

Lymphocyte Activation Gene 3-a Novel Therapeutic Target in Chronic Lymphocytic Leukemia

Real-Life Experience of Nivolumab in Heavily Pretreated Relapsed and Refractory Classical Hodgkin Lymphoma

SLP76 Is Ectopically Expressed in Chronic Lymphocytic Leukemia Cells and Involves in B-Cell Receptor Signaling

Comparison of the Low Toxicity Tecam Conditioning Regimen to BEAM in Patients with Lymphoma Requiring Autologous Stem Cell Transplantation

Primary Splenic Diffuse Large B-Cell Lymphoma (PS-DLBCL): Splenectomy Improves Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only